What is Valinor?
Valinor is at the forefront of therapeutic R&D, leveraging machine learning and proprietary clinical datasets to accelerate drug discovery. The company is developing a suite of patient-derived datasets and predictive models designed to assist drug developers in forecasting patient response. By mitigating trial-and-error processes and reducing development risks, Valinor aims to expedite breakthroughs across various therapeutic areas and drug modalities, positioning itself as a key innovator in the health tech sector.
How much funding has Valinor raised?
Valinor has raised a total of $13M across 1 funding round:
Seed
$13M
Seed (2025): $13M with participation from Pelion Venture Partners, Harpoon Ventures, Amino Collective, and Charles River Ventures
Key Investors in Valinor
Pelion Venture Partners
Pelion Venture Partners manages a portfolio of funds, offering investment solutions tailored for institutional and individual clients seeking diversified opportunities.
Harpoon Ventures
Harpoon Ventures backs leaders in mission-critical technologies, including AI and deep tech, aiming to restore American technological leadership and provide strategic advantages.
Amino Collective
Amino Collective invests in the health and bio sectors, supporting early-stage European ventures with global scaling ambitions and innovative founders.
What's next for Valinor?
With this substantial backing, Valinor is poised to scale its operations and further refine its predictive modeling capabilities. The strategic investment will likely fuel expansion into new therapeutic markets and enhance its data infrastructure. Future endeavors may include strategic partnerships with major pharmaceutical companies and the broadening of its dataset offerings, solidifying its role in de-risking and accelerating the drug development pipeline.
See full Valinor company page
